A STUDY OF TREATMENT DISCONTINUATION FOR CHRONIC HEPATITIS B PATIENTS

Grant number: 1066536 | Funding period: 2014 - 2018

Completed

Abstract

Guidelines currently recommend lifelong treatment for patients with chronic hepatitis B, with associated cost and risks of drug resistance and side effects. It has recently been suggested that up to 50% of patients may safely and successfully stop drug after long-term treatment. Our project will identify which patients can safely stop treatment, by performing detailed studies of the human immune system and the hepatitis B virus. This will be an important advance for patient care.

Related publications (4)

Scholarly works icon

Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways

Samuel Al Hall, Gareth S Burns, Benjamin J Mooney, Rosemary Millen, Rachel Morris, Sara Vogrin, Vijaya Sundararajan, Dilip Ratnam, Miriam T Levy, John S Lubel, Amanda J Nicoll, Simone Strasser, William Sievert, Paul Desmond, Meng C Ngu, Peter Angus, Marie Sinclair, Christopher Meredith, Gail Matthews, Peter A Revill

2022-09-15

BACKGROUND: We evaluated the patterns of peripheral Toll-like receptor (TLR) signaling activity and the expression of TLRs and nat..

Scholarly works icon

Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

Samuel AL Hall, Gareth S Burns, Despina Anagnostou, Sara Vogrin, Vijaya Sundararajan, Dilip Ratnam, Miriam T Levy, John S Lubel, Amanda J Nicoll, Simone Strasser, William Sievert, Paul Desmond, Meng C Ngu, Peter Angus, Marie Sinclair, Christopher Meredith, Gail Matthews, Peter A Revill, Kathy Jackson, Margaret Littlejohn

2022-05-06

BACKGROUND AND AIMS: Current guidelines recommend long-term nucleot(s)ide analogue (NA) therapy for patients with HBeAg-negative c..

Scholarly works icon

Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis

Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson

2021-09-07

BACKGROUND AND AIMS: Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucl..

Scholarly works icon

Secreted and intracellular cytokines are complementary measures for human monocytes treated with Toll-like receptor agonists

Yang Song, Julie Nigro, Lijia Yu, Mario Congiu, Narelle Skinner, Alexander Thompson, Kumar Visvanathan

2019-01-01

Cytokine production by human peripheral blood mononuclear cells including monocytes, is frequently assessed by measuring secreted ..